Home > Institute Collections > BN DZNE > BN DZNE-LIS > Influenza A Virus as a Predisposing Factor for Cryptococcosis > print

001     284089
005     20260126112352.0
024 7 _ |a 10.3389/fcimb.2017.00419
|2 doi
037 _ _ |a DZNE-2026-00097
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Oliveira, Lorena V. N.
|b 0
245 _ _ |a Influenza A Virus as a Predisposing Factor for Cryptococcosis
260 _ _ |a Lausanne
|c 2017
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769418636_1866
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Influenza A virus (IAV) infects millions of people annually and predisposes to secondary bacterial infections. Inhalation of fungi within the Cryptococcus complex causes pulmonary disease with secondary meningo-encephalitis. Underlying pulmonary disease is a strong risk factor for development of C. gattii cryptococcosis though the effect of concurrent infection with IAV has not been studied. We developed an in vivo model of Influenza A H1N1 and C. gattii co-infection. Co-infection resulted in a major increase in morbidity and mortality, with severe lung damage and a high brain fungal burden when mice were infected in the acute phase of influenza multiplication. Furthermore, IAV alters the host response to C. gattii, leading to recruitment of significantly more neutrophils and macrophages into the lungs. Moreover, IAV induced the production of type 1 interferons (IFN-α4/β) and the levels of IFN-γ were significantly reduced, which can be associated with impairment of the immune response to Cryptococcus during co-infection. Phagocytosis, killing of cryptococci and production of reactive oxygen species (ROS) by IAV-infected macrophages were reduced, independent of previous IFN-γ stimulation, leading to increased proliferation of the fungus within macrophages. In conclusion, IAV infection is a predisposing factor for severe disease and adverse outcomes in mice co-infected with C. gattii.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a Cryptococcosis
|2 Other
650 _ 7 |a Cryptococcus gattii
|2 Other
650 _ 7 |a co-infection
|2 Other
650 _ 7 |a influenza A H1N1
|2 Other
650 _ 7 |a risk factor
|2 Other
650 _ 7 |a Chemokines
|2 NLM Chemicals
650 _ 7 |a Cytokines
|2 NLM Chemicals
650 _ 7 |a IFNG protein, mouse
|2 NLM Chemicals
650 _ 7 |a Reactive Oxygen Species
|2 NLM Chemicals
650 _ 7 |a Peroxynitrous Acid
|0 14691-52-2
|2 NLM Chemicals
650 _ 7 |a Nitric Oxide
|0 31C4KY9ESH
|2 NLM Chemicals
650 _ 7 |a Interferon-gamma
|0 82115-62-6
|2 NLM Chemicals
650 _ 7 |a Peroxidase
|0 EC 1.11.1.7
|2 NLM Chemicals
650 _ 7 |a Acetylglucosaminidase
|0 EC 3.2.1.52
|2 NLM Chemicals
650 _ 2 |a Acetylglucosaminidase: metabolism
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Behavior, Animal
|2 MeSH
650 _ 2 |a Brain: microbiology
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Causality
|2 MeSH
650 _ 2 |a Cell Proliferation
|2 MeSH
650 _ 2 |a Chemokines: metabolism
|2 MeSH
650 _ 2 |a Coinfection: immunology
|2 MeSH
650 _ 2 |a Coinfection: microbiology
|2 MeSH
650 _ 2 |a Coinfection: mortality
|2 MeSH
650 _ 2 |a Coinfection: virology
|2 MeSH
650 _ 2 |a Cryptococcosis: complications
|2 MeSH
650 _ 2 |a Cryptococcosis: immunology
|2 MeSH
650 _ 2 |a Cryptococcus gattii: immunology
|2 MeSH
650 _ 2 |a Cryptococcus gattii: pathogenicity
|2 MeSH
650 _ 2 |a Cryptococcus neoformans: immunology
|2 MeSH
650 _ 2 |a Cytokines: metabolism
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Disease Susceptibility
|2 MeSH
650 _ 2 |a Dogs
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Influenza A Virus, H1N1 Subtype: immunology
|2 MeSH
650 _ 2 |a Influenza A Virus, H1N1 Subtype: pathogenicity
|2 MeSH
650 _ 2 |a Interferon-gamma: metabolism
|2 MeSH
650 _ 2 |a Lung: enzymology
|2 MeSH
650 _ 2 |a Lung: pathology
|2 MeSH
650 _ 2 |a Lung: virology
|2 MeSH
650 _ 2 |a Macrophages: metabolism
|2 MeSH
650 _ 2 |a Macrophages: virology
|2 MeSH
650 _ 2 |a Madin Darby Canine Kidney Cells
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Neutrophils
|2 MeSH
650 _ 2 |a Nitric Oxide: metabolism
|2 MeSH
650 _ 2 |a Orthomyxoviridae Infections: complications
|2 MeSH
650 _ 2 |a Orthomyxoviridae Infections: immunology
|2 MeSH
650 _ 2 |a Peroxidase: metabolism
|2 MeSH
650 _ 2 |a Peroxynitrous Acid: metabolism
|2 MeSH
650 _ 2 |a Phagocytosis
|2 MeSH
650 _ 2 |a Reactive Oxygen Species: metabolism
|2 MeSH
650 _ 2 |a Survival Rate
|2 MeSH
700 1 _ |a Costa, Marliete C.
|b 1
700 1 _ |a Magalhães, Thaís F. F.
|b 2
700 1 _ |a Bastos, Rafael W.
|b 3
700 1 _ |a Campi Santos, Patricia
|0 P:(DE-2719)9003461
|b 4
|u dzne
700 1 _ |a Carneiro, Hellem C. S.
|b 5
700 1 _ |a Ribeiro, Noelly Q.
|b 6
700 1 _ |a Ferreira, Gabriella F.
|b 7
700 1 _ |a Secchim Ribeiro, Lucas
|0 P:(DE-2719)9001782
|b 8
|u dzne
700 1 _ |a Gonçalves, Ana P. F.
|b 9
700 1 _ |a Fagundes, Caio T.
|b 10
700 1 _ |a Pascoal-Xavier, Marcelo A.
|b 11
700 1 _ |a Djordjevic, Julianne T.
|b 12
700 1 _ |a Sorrell, Tania C.
|b 13
700 1 _ |a Souza, Daniele G.
|b 14
700 1 _ |a Machado, Alexandre M. V.
|b 15
700 1 _ |a Santos, Daniel A.
|b 16
773 _ _ |a 10.3389/fcimb.2017.00419
|g Vol. 7, p. 419
|0 PERI:(DE-600)2619676-1
|p 419
|t Frontiers in Cellular and Infection Microbiology
|v 7
|y 2017
|x 2235-2988
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/284089/files/fcimb-07-00419.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/284089/files/fcimb-07-00419.pdf?subformat=pdfa
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9003461
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)9001782
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT CELL INFECT MI : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-12-06T06:41:59Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-12-06T06:41:59Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-12-06T06:41:59Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT CELL INFECT MI : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a Hosted Content
|0 StatID:(DE-HGF)10000
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 _ _ |l yes
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1040260
980 1 _ |a UNRESTRICTED
980 1 _ |a EXTERN4VITA
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21